-
1.发明授权Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators 失效异噻唑-3（2H） - 酮1,1-二氧化物的衍生物作为肝X受体调节剂公开(公告)号：US07582629B2
公开(公告)日：2009-09-01
申请号：US11813481
申请日：2006-01-09
申请人： Jonas Boström , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
发明人： Jonas Boström , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
IPC分类号： A61K31/535 , A61K31/445 , A61K31/425 , C07D415/00 , C07D413/00 , C07D417/00 , C07D275/02
CPC分类号： C07D275/03 , C07D417/12
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
2.发明申请DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR 审中-公开异硫氰酸-3（2H） - 酮-1,1-二氧化物作为肝脏X受体调节剂的衍生物公开(公告)号：US20100016321A1
公开(公告)日：2010-01-21
申请号：US12507924
申请日：2009-07-23
申请人： Jonas Bostrom , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
发明人： Jonas Bostrom , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
IPC分类号： A61K31/5377 , A61P3/00 , A61P25/00
CPC分类号： C07D275/03 , C07D417/12
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，用于制备这些化合物的方法，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和治疗 和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
3.发明申请Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators 失效异噻唑-3（2H） - 一种1,1-二氧化物作为肝X受体调节剂的衍生物公开(公告)号：US20080255122A1
公开(公告)日：2008-10-16
申请号：US11813481
申请日：2006-01-09
申请人： Jonas Bostrom , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
发明人： Jonas Bostrom , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
IPC分类号： A61K31/5355 , C07D275/03 , A61K31/425 , A61P25/00 , C07D401/02 , A61K31/497 , A61K31/4725 , C07D413/14 , A61K31/454 , C07D417/02
CPC分类号： C07D275/03 , C07D417/12
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
4.发明授权Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators 失效异噻唑-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US07960380B2
公开(公告)日：2011-06-14
申请号：US12725669
申请日：2010-03-17
申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
发明人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
IPC分类号： A61K31/5355 , A61K31/501 , A61K31/4523 , A61K31/4427 , A61K31/427 , A61K31/4255 , C07D275/02 , C07D233/54 , C07D413/02 , C07D401/02 , C07D239/02 , C07D211/00 , C07D417/02
CPC分类号： C07D275/03 , C07D417/12 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新型化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或bgr; （NR1H2）和治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
5.发明申请Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators 失效异噻唑啉-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US20100227847A1
公开(公告)日：2010-09-09
申请号：US12725669
申请日：2010-03-17
申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
发明人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
IPC分类号： A61K31/427 , A61P3/10 , A61P3/06 , A61P9/10 , A61P25/28 , A61K31/425 , A61K31/4439 , A61K31/4545 , A61K31/454 , A61K31/5377
CPC分类号： C07D275/03 , C07D417/12 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新型化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或bgr; （NR1H2）和治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
6.发明授权Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators 失效异噻唑-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US07723333B2
公开(公告)日：2010-05-25
申请号：US11813470
申请日：2006-01-09
申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
发明人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
IPC分类号： A61K31/5355 , A61K31/501 , A61K31/4523 , A61K31/4427 , A61K31/427 , A61K31/4155 , C07D275/02 , C07D233/54 , C07D413/02 , C07D401/02 , C07D239/02 , C07D211/00 , C07D417/02
CPC分类号： C07D275/03 , C07D417/12 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新型化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或bgr; （NR1H2）和治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
7.发明申请Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators 失效异噻唑啉-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US20090005353A1
公开(公告)日：2009-01-01
申请号：US11813470
申请日：2006-01-09
申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
发明人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
IPC分类号： A61K31/397 , C07D275/02 , A61K31/425 , C07D417/02 , A61K31/4439 , C07D211/06 , A61K31/4545 , A61K31/501 , A61P29/00 , A61P25/00 , A61P9/00 , C07D403/14 , A61K31/454 , C07D401/14 , A61K31/506 , C07D295/00 , A61K31/5377
CPC分类号： C07D275/03 , C07D417/12 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
公开(公告)号：US07432288B2
公开(公告)日：2008-10-07
申请号：US10564235
申请日：2004-07-08
申请人： Jonas Boström , Kay Brickmann , Patrik Holm , Pernilla Sandberg , Marianne Swanson , Christer Westerlund
发明人： Jonas Boström , Kay Brickmann , Patrik Holm , Pernilla Sandberg , Marianne Swanson , Christer Westerlund
IPC分类号： A61K31/4439 , C07D401/04
CPC分类号： C07D405/06 , C07D207/456 , C07D401/06 , C07D405/12 , C07D405/14 , C07D413/06
摘要： The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR)α(NR1H3) and/or β(NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及一些式I化合物的制备方法，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）以及在治疗和 /或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
公开(公告)号：US20060235015A1
公开(公告)日：2006-10-19
申请号：US10564235
申请日：2004-07-08
IPC分类号： A61K31/5377 , A61K31/4439 , A61K31/4015 , A61K31/4025 , C07D413/02 , C07D405/02 , C07D403/02
CPC分类号： C07D405/06 , C07D207/456 , C07D401/06 , C07D405/12 , C07D405/14 , C07D413/06
摘要： The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及一些式I化合物的制备方法，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）以及在治疗和 /或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
10.发明申请Non-Anilinic Derivatives Of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators 审中-公开异噻唑啉-3（2H） - 二氧化铅的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US20080139616A1
公开(公告)日：2008-06-12
申请号：US11813458
申请日：2006-01-09
申请人： Lanna Li , Marianne Swanson , Kay Brickmann
发明人： Lanna Li , Marianne Swanson , Kay Brickmann
IPC分类号： A61K31/4523 , C07D221/00 , A61K31/425 , A61P9/00 , C07D275/02
CPC分类号： C07D275/03 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.064 秒)
